Novozymes A/S Valuation
| NVZMF Stock | USD 59.48 1.98 3.44% |
At this time, the firm appears to be overvalued. Novozymes AS B secures a last-minute Real Value of $51.37 per share. The latest price of the firm is $59.48. Our model forecasts the value of Novozymes AS B from analyzing the firm fundamentals such as Return On Equity of 0.28, profit margin of 0.21 %, and Current Valuation of 14.47 B as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Novozymes A/S's price fluctuation is very steady at this time. Calculation of the real value of Novozymes AS B is based on 3 months time horizon. Increasing Novozymes A/S's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novozymes pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Novozymes AS B. Since Novozymes A/S is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novozymes Pink Sheet. However, Novozymes A/S's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 59.48 | Real 51.37 | Hype 59.48 | Naive 59.32 |
The real value of Novozymes Pink Sheet, also known as its intrinsic value, is the underlying worth of Novozymes AS B Company, which is reflected in its stock price. It is based on Novozymes A/S's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Novozymes A/S's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Novozymes AS B helps investors to forecast how Novozymes pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novozymes A/S more accurately as focusing exclusively on Novozymes A/S's fundamentals will not take into account other important factors: Novozymes A/S Total Value Analysis
Novozymes AS B is now expected to have takeover price of 14.47 B with market capitalization of 13.95 B, debt of 7.31 B, and cash on hands of 1.01 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Novozymes A/S fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.47 B | 13.95 B | 7.31 B | 1.01 B |
Novozymes A/S Investor Information
About 42.0% of the company shares are owned by institutional investors. The company last dividend was issued on the 3rd of March 2023. Novozymes AS B had 5:1 split on the 28th of November 2011. Based on the key indicators related to Novozymes A/S's liquidity, profitability, solvency, and operating efficiency, Novozymes AS B is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Novozymes A/S Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novozymes A/S has an asset utilization ratio of 62.73 percent. This implies that the Company is making $0.63 for each dollar of assets. An increasing asset utilization means that Novozymes AS B is more efficient with each dollar of assets it utilizes for everyday operations.Novozymes A/S Ownership Allocation
Novozymes AS B maintains a total of 222.86 Million outstanding shares. 30% of Novozymes A/S outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Novozymes A/S Profitability Analysis
The company reported the revenue of 17.55 B. Net Income was 3.68 B with profit before overhead, payroll, taxes, and interest of 9.59 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Novozymes A/S's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Novozymes A/S and how it compares across the competition.
About Novozymes A/S Valuation
The pink sheet valuation mechanism determines Novozymes A/S's current worth on a weekly basis. Our valuation model uses a comparative analysis of Novozymes A/S. We calculate exposure to Novozymes A/S's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novozymes A/S's related companies.Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States.
8 Steps to conduct Novozymes A/S's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novozymes A/S's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novozymes A/S's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Novozymes A/S's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Novozymes A/S's revenue streams: Identify Novozymes A/S's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Novozymes A/S's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Novozymes A/S's growth potential: Evaluate Novozymes A/S's management, business model, and growth potential.
- Determine Novozymes A/S's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novozymes A/S's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Novozymes A/S Growth Indicators
Investing in growth stocks can be very risky. If the company such as Novozymes A/S does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 276.6 M | |
| Quarterly Earnings Growth Y O Y | 0.42 | |
| Forward Price Earnings | 29.6736 | |
| Retained Earnings | 13.1 B |
Complementary Tools for Novozymes Pink Sheet analysis
When running Novozymes A/S's price analysis, check to measure Novozymes A/S's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novozymes A/S is operating at the current time. Most of Novozymes A/S's value examination focuses on studying past and present price action to predict the probability of Novozymes A/S's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novozymes A/S's price. Additionally, you may evaluate how the addition of Novozymes A/S to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |